"Migraine Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Descriptor ID |
D008881
|
| MeSH Number(s) |
C10.228.140.546.399.750
|
| Concept/Terms |
Migraine Disorders- Migraine Disorders
- Disorder, Migraine
- Disorders, Migraine
- Migraine Disorder
- Migraine
- Migraines
- Migraine Headache
- Headache, Migraine
- Headaches, Migraine
- Migraine Headaches
Acute Confusional Migraine- Acute Confusional Migraine
- Acute Confusional Migraines
- Migraine, Acute Confusional
- Migraines, Acute Confusional
Hemicrania Migraine- Hemicrania Migraine
- Hemicrania Migraines
- Migraine, Hemicrania
- Migraines, Hemicrania
Migraine Variant- Migraine Variant
- Migraine Variants
- Variant, Migraine
- Variants, Migraine
Sick Headache- Sick Headache
- Headache, Sick
- Headaches, Sick
- Sick Headaches
Abdominal Migraine- Abdominal Migraine
- Abdominal Migraines
- Migraine, Abdominal
- Migraines, Abdominal
Cervical Migraine Syndrome- Cervical Migraine Syndrome
- Cervical Migraine Syndromes
- Migraine Syndrome, Cervical
- Migraine Syndromes, Cervical
|
Below are MeSH descriptors whose meaning is more general than "Migraine Disorders".
Below are MeSH descriptors whose meaning is more specific than "Migraine Disorders".
This graph shows the total number of publications written about "Migraine Disorders" by people in this website by year, and whether "Migraine Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2002 | 15 | 1 | 16 |
| 2003 | 22 | 2 | 24 |
| 2004 | 29 | 1 | 30 |
| 2005 | 24 | 1 | 25 |
| 2006 | 23 | 3 | 26 |
| 2007 | 28 | 1 | 29 |
| 2008 | 30 | 3 | 33 |
| 2009 | 26 | 5 | 31 |
| 2010 | 22 | 2 | 24 |
| 2011 | 12 | 2 | 14 |
| 2012 | 13 | 1 | 14 |
| 2013 | 12 | 1 | 13 |
| 2014 | 12 | 0 | 12 |
| 2015 | 11 | 3 | 14 |
| 2016 | 12 | 0 | 12 |
| 2017 | 12 | 1 | 13 |
| 2018 | 25 | 0 | 25 |
| 2019 | 18 | 0 | 18 |
| 2020 | 8 | 0 | 8 |
| 2021 | 17 | 0 | 17 |
| 2022 | 17 | 0 | 17 |
| 2023 | 9 | 0 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Migraine Disorders" by people in Profiles.
-
Li D, Abreu J, Tepper SJ. A Brief Review of Gepants. Curr Pain Headache Rep. 2023 Sep; 27(9):479-488.
-
Charleston L, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, Soni-Brahmbhatt S, Nahas SJ. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study. J Headache Pain. 2023 Aug 02; 24(1):101.
-
Tepper SJ, Lipton RB, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Wang A, Cheng S, Klatt J, Mikol DD. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache. 2023 Jun; 63(6):730-742.
-
Rist PM, Buring JE, Cook NR, Kurth T. Contribution of Migraine to Cardiovascular Disease Risk Prediction. J Am Coll Cardiol. 2023 06 13; 81(23):2246-2254.
-
Tepper SJ, Cirillo J, Kim E, L'Italien G, Tweedie JM, Lodaya K, Riley D, Pathan F, Antaki N, Nathanson BH, McAllister P. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression. J Headache Pain. 2023 May 16; 24(1):54.
-
Begasse de Dhaem O, Takizawa T, Dodick DW. Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. Cephalalgia. 2023 02; 43(2):3331024221137092.
-
Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023 Jan; 63(1):79-88.
-
Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, Diamond M, Marmura MJ, Guo H, Finnegan M, Trugman JM. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia. 2023 Jan; 43(1):3331024221128250.
-
George N, Tepper SJ. Novel Migraine Treatments: A Review. J Oral Facial Pain Headache. 2023 Winter; 37(1):27-34.
-
Gollion C, De Icco R, Dodick DW, Ashina H. The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence. J Headache Pain. 2022 Dec 13; 23(1):158.